Head-to-head evidence
Brigatinib vs Ensartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Brigatinib
Marketed by Takeda Pharmaceutical Company
NCT02737501 · Phase 3 · completed
This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT04223596 (registry estimate)
Ensartinib
Marketed by Xcovery Holdings
NCT01625234 · Phase 1/2 · completed
This was a non-randomized, open-label, single-arm study with 131 participants and no placebo or active comparator. Its primary endpoint was the maximum tolerated dose, a dose-finding safety outcome rather than a clinical efficacy endpoint, so the findings provide limited controlled evidence for ensartinib’s treatment benefit.
Next expected readout: February 2027 · NCT05241028 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brigatinib's landscape · Ensartinib's landscape